November 15, 2018
Loading Events

« All Events

SMi Presentsthe2nd Annual Conference: Ophthalmic Drugs

November 26 - November 27

SMi’s 2nd annual Ophthalmic Drugs conference returning to London, takes place at the Copthorne Tara Hotel in Kensington, on the 26th – 27th November 2018.

As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

Building on last year’s success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive, half-day post-conference workshops on 28th November 2018, led by twoXAR and Aston University

This Year’s Agenda Highlights Include:

  • Discover recent advances in the treatment of glaucoma
  • Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
  • Discuss case studies on novel non-invasive and site-specific drug delivery strategies
  • Examine the applications of artificial intelligence in drug discovery
  • Explore use of biomarkers and surrogate end-points from a regulatory perspective

Chairs for 2018:

  • Mitchell de long, Vice President, Chemistry, AeriePharmaceuticals
  • Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen

Key Speakers:

  • Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
  • Caroline Barelle, CEO, Elasmogen
  • Victor Chong, Global Head of Ophthalmology, BoehringerIngelheim
  • Daniel Chung, Clinical Ophthalmic Lead, SparkTherapeutics
  • AnizGirach, Chief Medical Officer, NightstarTherapeutics
  • Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
  • David Silverman, Clinical Director, Ophthalmology, Roche

View the full agenda online: www.ophthalmicdrugs.com/pnhq

EARLY-BIRD RATES:

  • REGISTER BY 29TH JUNE AND SAVE £300
  • REGISTER BY 28TH SEPTEMBER AND SAVE £200
  • REGISTER BY 31ST OCTOBER AND SAVE £100

Social Media Handles

Targeted Keywords

ophthalmic drug development, ophthalmic, ophthalmology, vision, diabetic retinopathy, ocular diseases, medical devices, nanotechnology, drug delivery, glaucoma, AMD, optical, optic, optometrist, ophthalmologist, eye, eyecare, visual, diabetes

Additional Contact Info:

T: +44 (0)20 7827 6048
E: psolanki@smi-online.co.uk

Details

Start:
November 26
End:
November 27
Website:
http://www.ophthalmicdrugs.com/pnhq

Organizer

SMI
Phone:
+44 (0)20 7827 6048
Email:
psolanki@smi-online.co.uk

Venue

Copthorne Tara Hotel, London UK

To ensure you get the best experience on our website, we use cookies to analyze traffic and for ads measurements purposes including for serving Industry-based ads. By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close